Currently trailing Eli Lilly and Structure Therapeutics in the oral weight loss space, Novo Nordisk strikes a deal with Septerna to put new discovery-stage programs into play.
Novo Doubles Down on Oral Obesity Meds With Septerna Deal Worth up to $2.4B Read More »
Sen. Chuck Grassley, R-Iowa, suggested Congress could once again move to overhaul PBMs’ controversial business practices after legislators pass President Donald Trump’s conservative megabill this summer.
En un momento en el que la cirugía estética se ha popularizado y en algunos casos banalizado, la figura del Dr. Félix Chavarría destaca como un ejemplo de ética médica, innovación quirúrgica y compromiso con el bienestar integral del …
While venture funding is rising, federal policy upheaval may affect women’s health research more acutely than other fields, one biotech CEO said.
Women’s health faces growing headwinds, despite jump in venture investment Read More »
Microsoft Excel es una herramienta esencial para millones de personas en todo el mundo. Se utiliza ampliamente en análisis de datos, modelado financiero y numerosas tareas cotidianas. Sin embargo, a veces, los usuarios se encuentran en la desagradable situación de no poder recuperar un …
Cómo recuperar un archivo de Excel no guardado que no aparece en la recuperación Read More »
Roche envisions its Indianapolis site as a “major hub” for the manufacturing of its continuous glucose monitoring systems. The news comes on the heels of an announced $700 million investment in North Carolina.
Roche Continues US Investments With $550M Diagnostics Push in Lilly’s Backyard Read More »
Arcturus is extending its cash runway into 2028 by discontinuing its early-stage vaccine candidates.
Arcturus Prunes Early-Stage Pipeline, Leans Into mRNA Therapies Read More »
Belrestotug showed underwhelming efficacy outcomes in mid-stage studies of non-small cell lung cancer and head and neck squamous cell carcinoma.
GSK, iTeos Abandon TIGIT Therapy, Adding to Long List of Recent Class Failures Read More »
The commission is taking steps to target roughly $107 billion worth of imports if it can’t make a tariff deal with the U.S.
European Commission readies countermeasures to US tariffs Read More »
GSK secures rights to Boston Pharmaceuticals’ efimosfermin alfa, which the pharma plans to develop for fatty liver diseases such as metabolic dysfunction-associated steatohepatitis and alcohol-related liver disease.
GSK Buys Phase III–Ready Liver Drug in Potential $2B Deal To Play in MASH Arena Read More »
